Preclinical studies show ACT-903 demonstrates tumor suppression, increased survival, maytansine and metabolite accumulation in the tumor, and no signs of toxicity TORONTO--(BUSINESS WIRE)--Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Health Canada has approved the New Drug Submission (NDS-CV) for SPIKEVAX™ (elasomeran mRN
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES VANCOUVER, British Columbia--(BUSINESS WIRE)--Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) (“Sproutly" or the “Company”) announces that it intends to settle outstanding c
Precision imaging for precision medicine THUNDER BAY & TORONTO, Ontario--(BUSINESS WIRE)--Radialis Medical today announced that it has submitted a U.S. Food & Drug Administration (FDA) 510(k) premarket notification for the Radialis PET Camera, an org
Flora signs Letter of Intent with an international importer and distributor based in Panama to provide cannabinoid containing food and beverages through its Kasa Wholefoods division, and finished cannabis derivative products for medical cannabis patient
OTTAWA, Ontario--(BUSINESS WIRE)--$BWXT--BWX Technologies, Inc. (NYSE: BWXT) announced today that its BWXT Medical Ltd. subsidiary (BWXT Medical) has entered into an agreement with Bayer AG (Bayer) to develop Actinium-225 (Ac-225) supply and further partn
Confirmed objective response rate (cORR) of 75% overall and 93% for the proposed Phase 3 regimen (zanidatamab + CAPOX/FP) Median duration of response (mDOR) of 16.4 months and median progression free survival (mPFS) of 12 months Data support zanidat
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will present at the following upcoming virtual investor conferences: Oppenheimer Fall
Partnership combines AbCellera’s AI-powered antibody discovery platform with Moderna’s mRNA technology platform to accelerate the development of mRNA-encoded antibody therapeutics across multiple indications VANCOUVER, British Columbia--(BUSINESS WIR
VANCOUVER, British Columbia--(BUSINESS WIRE)--$CALM #CANADIANSECURITIESEXCHANGE--REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (CSNX: CALM.CN) is pleased to formally announce the opening of its fifth psychedeli
Congratulations to BAM member XiteBio Technologies Inc.!
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.